New guidelines for taking cholesterol-lowering drugs target cardiovascular risk, not cholesterol level

For years, doctors prescribed the cholesterol-lowering drugs known as statins based largely on cholesterol test results. But new guidelines from the American Heart Association and the American College of Cardiology propose a major change to that strategy, reports the February 2014 Harvard Heart Letter. "The new guidelines shift away from a target-driven approach to a risk-driven approach," says Dr. Reena Pande, a cardiologist at Harvard-affiliated Brigham and Women's Hospital and an instructor in medicine at Harvard Medical School. Instead of striving to reach a specific cholesterol value, doctors should consider a person's entire cardiovascular risk profile, she explains. The biggest change is for those who don't have heart disease but are at risk for it. For them, doctors should use the risk calculator on the American Heart Association's website to help determine if taking a statin makes sense. The calculator considers age, sex, race, total cholesterol, "good" HDL cholesterol, blood pressure, diabetes, and smoking history. One thing the guidelines don't take into account, however, is family history, Dr. Pande notes. Anyone with a parent who was diagnosed with heart disease before age 50 is at higher-than-average risk, regardless of cholesterol level. The guidelines also help doctors identify the right statin at the right dose. For example, someone with a history of heart disease may need a high-intensity statin such as atorvastatin (Lipitor), while someo...
Source: New Harvard Health Information - Category: Consumer Health News Source Type: news

Related Links:

Diabetes Metab J. 2021 Jul;45(4):492-501. doi: 10.4093/dmj.2020.0262. Epub 2021 Jul 30.ABSTRACTCardiovascular disease is the primary cause of mortality in women and men with diabetes. Due to age and worsening of risk factors over the menopausal transition, risk of coronary heart disease events increases in postmenopausal women with diabetes. Randomized studies have conflicted regarding the beneficial impact of estrogen therapy upon intermediate cardiovascular disease markers and events. Therefore, estrogen therapy is not currently recommended for indications other than symptom management. However, for women at low risk of ...
Source: Diabetes and Metabolism Journal - Category: Endocrinology Authors: Source Type: research
This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD).MethodsAnalyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80  years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (≥ 6 months to  0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statin...
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
Conclusions: The GermanVasc registry study provides insights into real-world practice of treatment and outcomes of 5,608 patients with symptomatic PAD in Germany. The cohort covers a broader range of disease severity and types of interventions than usually found in trials. In future studies, comparative outcomes will be analysed in more detail.PMID:34279120 | DOI:10.1024/0301-1526/a000966
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - Category: Surgery Authors: Source Type: research
In conclusion, the findings suggest that DNAm GrimAge is a strong predictor of mortality independent of genetic influences. Heart Failure Correlates with Increased Cancer Risk Age-related disease results from the underlying cell and tissue damage that causes aging. Different people accumulate that damage at modestly different rates, the result of lifestyle choices and exposure to infectious disease. Thus the presence of a sufficient burden of damage to produce one age-related disease will be accompanied by a ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
H. Hsu We use UK Biobank data to train predictors for 65 blood and urine markers such as HDL, LDL, lipoprotein A, glycated haemoglobin, etc. from SNP genotype. For example, our Polygenic Score (PGS) predictor correlates ∼0.76 with lipoprotein A level, which is highly heritable and an independent risk factor for heart disease. This may be the most accurate genomic prediction of a quantitative trait that has yet been produced (specifically, for European ancestry groups). We also train predictors of common disease risk using blood and urine biomarkers alone (no DNA information); we call these predictors biomarker ris...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
In conclusion, phthalate exposure was positively associated with CVD in Chinese with type 2 diabetes. Type 2 diabetic men who are currently smoking, have an uncontrolled lipid profile, and are not using statins might be more susceptible to CVD when exposed to phthalates.PMID:34109519 | DOI:10.1007/s11356-021-14807-4
Source: Environmental Science and Pollution Research International - Category: Environmental Health Authors: Source Type: research
STATINS provide a crucial buffer against heart disease by reducing bad cholesterol levels in the blood. However, research indicates that they can raise risk of diabetes at a certain frequency and dose.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
More News: Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Diabetes | Endocrinology | Harvard | Health | Heart | Heart Disease | Hospitals | Lipitor | Nutrition | Pravastatin | Smokers | Sports Medicine | Statin Therapy | Websites | Women | Zivast